AURA
Aura Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.29
+3.11%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -29.3%
- EBIT
- -27.0%
- EPS
- +9.2%
- Free cash flow
- -21.9%
- Operating cash flow
- -22.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +11.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -22.6%
- EBIT
- -17.3%
- Net income
- -22.2%
- EPS
- -0.6%
- Free cash flow
- -5.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026